This excerpt taken from the EYE 8-K filed May 31, 2005.
Advanced Medical Optics Completes Acquisition of VISX, Incorporated
SANTA ANA, Calif., May 31, 2005 Advanced Medical Optics, Inc. (AMO) (NYSE: AVO), announced today that it has completed its acquisition of VISX, Incorporated. The strategic combination brings together two highly complementary companies with a broad range of superior ophthalmic technologies and a singular focus on serving the vision care needs of practitioners and patients around the world.
AMO and VISX stockholders approved the transaction on May 26, 2005.
AMO announced on November 9, 2004 its agreement to acquire VISX in a cash and stock transaction. Under the terms of the definitive merger agreement, VISX stockholders receive 0.552 shares of AMO stock and $3.50 in cash for every share of VISX common stock they own.
We view refractive surgery as an extremely important growth opportunity in ophthalmic devices, said AMO President and CEO Jim Mazzo. The acquisition of VISX transforms AMO into the worlds leading refractive surgical company and demonstrates our commitment to this fast-growing market. AMO pioneered the concept of refractive intraocular lenses (IOLs) and currently offers more refractive IOLs worldwide than any other competitor. As we combine VISX with AMO, we will continue to focus our R&D investment toward discovering new technologies that optimize vision for people of all ages.
AMO inherits VISXs large installed base of industry leading brands such as the STAR(TM) S4 Laser System, WaveScan Wavefront(R) system and CustomVue(R) custom ablation technology. These products, in conjunction with AMOs refractive portfolio that includes Verisyse(R), ReZoom(TM), Array(R), and Tecnis(R) IOLs and the Amadeus(TM) II microkeratome, provides the largest portfolio of refractive products in the industry.
VISX is a company we have long admired, and I welcome our new colleagues and their superior product set and customer service excellence into the AMO organization, said Mazzo. We have strengthened our ability to serve eye care professionals and look forward to expanding the VISX technologies globally while continuing to provide products with the same safety, efficacy, convenience and options customers have grown to expect from AMO and VISX.
AMOs stockholders now own approximately 58.5 percent of the combined company and VISXs stockholders own approximately 41.5 percent. Effective June 8, AMO expects to begin trading on the New York Stock Exchange under the ticker symbol EYE.
Liz Davila, former chairman and CEO of VISX, has joined AMOs board of directors, while former VISX President and COO Doug Post joins AMO as president of its Americas region.